BioPegasus, LLC United States

BioPegasus, LLC specializes in a cost-effective and robust post-proteomics and post-protein and peptide array technology biomarker and target discovery technology platform. This proprietary platform is unique and transformative, allowing systematic, thorough and unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time. It aims to accelerate novel therapeutic and diagnostic development for some devastating diseases to improve our health and quality of life. These diseases include autoimmune diseases, cancer, and, in particular, Alzheimer’s disease.

BioPegasus' technology platform provides a revolutionary tool for systematical and thorough studying novel molecular interactions and mechanism of actions with any molecule of interest. The platform can be used to provide contract services with royalty payment potential to research institutions and companies in IVD, biotech and pharma sectors. The technology can also be packaged into commercial product(s) with a user manual for sale in the market world-wide.

BioPegasus currently is operated by its founder looking for an investor(s), partner(s), and sponsor(s)/client(s) or any form of collaboration/interest.

Website:
not available
Company Size (Fulltime employees)
Year of foundation
2006
Please specify your partnering goal
1) Seeking investment(s) for developing cost-effective and minimally invasive blood antibody biomarker tests for Alzheimer’s disease diagnosis and early detection (a 3-year project); and/or 2) Looking for any interested party(ies) to work together.
Headquartner in China
Assets Information 1
biomarker and target discovery technology platform|||
Biotech/Pharma Asset Stage
Your Research Tool and Service name
A unique and transformative λ phage cDNA expression library construction and screening (not phage display). A cost-effective and robust novel biomarker and target discovery technology platform for novel diagnostic and therapeutic development.
Service Description
BioPegasus' technology platform provides a revolutionary tool for systematically and thoroughly studying novel molecular interactions and mechanism of actions with any molecule of interest and allowing unambiguous discovery, identification and isolation of tissue-specific and disease-specific autoantigens and key disease drivers/proteins and their genes, and disease-specific antibodies in order to solve some most challenging problems of our time in novel diagnostic and therapeutic development.
Target client type
1) As diagnostic and early detection tests for Alzheimer's disease: general population for early detection (POCT, age 50 years and better) and patients for severity and diagnosis (lab tests); 2) As a research tool: client types include research institutions and diagnostic IVD, biotech and pharma companies
Slides Deck
(pdf, 957.61KB)
Dr. Tianlin Ma
Founder 
Functionality

ExpressCells United States

ExpressCells is genetic-engineering company that creates custom and catalog knock-in cell lines for biological research. Our approach uses CRISPR plus our patent-pending plasmid system that creates cell lines up to 75% faster than older technologies and allows multiple knock-ins. Our living cells replicate diseases or have proteins glow in multiple colors, speeding drug development. We are generating revenue through e-commerce, online promotion, and sales representatives.

Website:
xpresscells.com
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
Identify companies that can commercialize our cell lines in China and other Asian markets
Headquartner in China
Assets Information 1
Customer Knock-In Cell Lines
Assets Information 2
Catalog Cell Lines
Assets Information 3
Knock-in Stem Cells
Biotech/Pharma Asset Stage
Your Research Tool and Service name
Knock-in Cell Lines
Service Description
We create custom knock-in cell lines in as few as 30 days. Using our patent-pending FAST-HDR plasmid system, we can knock 1-3 genes into precise locations in cell lines. These knock-ins can be reporters, overexpression models, or have point mutations inserted.
Target client type
Research scientists in pharmaceuticals and biotech who conduct experiments on cell lines
Slides Deck
(pdf, 1.48MB)
Mr. Matt Handel
LinkedIn logo CEO 
Functionality

NurtureX United States

Strategy, Management and fundraising for genomic companies. Invest and help raise capital through private and public placements in the US, as well as guide company executives on Operational execution in the molecular diagnostics industry.

Company Size (Fulltime employees)
Please specify your partnering goal
Looking for new technologies and companies to invest and help with operational execution in the US
Headquartner in China
Medtech Category
Dr. Pankaj Singhal
LinkedIn logo President & CEO 
Functionality